Alkem Laboratories Limited (ALKEM)
Outcome of Board Meeting
FY2026 results:
Standalone:
Revenue 966.4bn +4% y-y (937.2bn)
EBITDA 210.7bn +10% y-y (191.4bn)
EBITDA margin 21.8% (20.4%) +140 bps y-y
PAT 228.2bn +5% y-y (217.3bn)
Consolidated:
Revenue 1,471.2bn +7% y-y (1,374.1bn)
EBITDA 304.6bn +8% y-y (281.0bn)
EBITDA margin 20.7% (20.5%) +20 bps y-y
PAT 235.1bn +7% y-y (219.4bn)
Dividend: Not stated
Commentary: The Group completed acquisition of majority stake in Occlutech Holding AG, Switzerland, post quarter end with no impact on Q1 results.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 ALKEM — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add ALKEM to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Alkem Laboratories Limited
Important.
The summary above is generated automatically from Alkem Laboratories Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.